INTERLACE Study: Real-world Data for Germany Based on a Case Series of Patients with Locally Advanced Cervical Cancer
Alina Lohner1, Volkmar Müller1, Andrea Baehr2
1Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Geburtshilfe Und Frauenheilkunde
|April 23, 2026
Summary
The INTERLACE regimen, adding induction chemotherapy before chemoradiotherapy for advanced cervical cancer, was cautiously adopted in Germany. Early results show feasibility in a small patient cohort, with most completing treatment.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
Background:
- Chemoradiotherapy is standard for locally advanced cervical cancer.
- The INTERLACE study evaluated adding induction chemotherapy (carboplatin and paclitaxel) prior to chemoradiotherapy.
- Adoption of the INTERLACE regimen in Germany has been cautious.
Purpose of the Study:
- To describe the adaptation and feasibility of the INTERLACE regimen in routine clinical practice in Germany.
- To evaluate patient outcomes and treatment completion rates.
Main Methods:
- Retrospective evaluation of seven patients with advanced cervical cancer treated with the INTERLACE regimen at a single center.
- Analysis of treatment duration, chemotherapy cycles, and radiotherapy completion.
Main Results:
- All seven patients received the planned six cycles of induction chemotherapy.
- Median time from chemotherapy completion to radiotherapy start was 10 days.
- Most patients completed radiotherapy and received concomitant chemotherapy, with few discontinuations due to toxicity.
Conclusions:
- The INTERLACE regimen appears feasible for selected patients with advanced cervical cancer in a German clinical setting.
- Further studies are needed to confirm efficacy and long-term outcomes.
